Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.60 -0.72 (-0.77%)
Streaming Delayed Price Updated: 12:28 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
74 75 Next >
News headline image
Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers ↗
The White House is endorsing a contentious power that permits the government to reclaim patents for specific  
Via Benzinga
Topics Intellectual Property
News headline image
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report ↗
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments ↗
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of... 
Via Talk Markets
News headline image
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers ↗
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies... 
Via Benzinga
News headline image
Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry ↗
 
Via Benzinga
News headline image
Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors ↗
 
Via Benzinga
News headline image
AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits ↗
AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE- 
Via Benzinga
News headline image
AstraZeneca advances scientific leadership in hematology at ASH 2023
From AstraZeneca
Via Business Wire
News headline image
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem ↗
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront... 
Via Talk Markets
News headline image
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant ↗
Could AstraZeneca be an under-rated buy right now? 
Via The Motley Fool
News headline image
3 No-Brainer Stocks to Buy With $1,000 Right Now ↗
A modest amount of money can go a long way when it's invested in industry-leading businesses with sustained, long-term catalysts. 
Via The Motley Fool
News headline image
5 Growth Stocks to Buy for 2024 ↗
Forget the "Magnificent 7." These are the top five growth stocks to buy in the coming year for interested investors. 
Via InvestorPlace
News headline image
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
From AstraZeneca
Via Business Wire
News headline image
3 stocks that crushed earnings estimates and still tanked
Every earnings season, regardless of sector or industry, has its share of stocks that go down even after beating earnings expectations such as these stocks 
Via MarketBeat
News headline image
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges ↗
The U.S. 
Via Benzinga
News headline image
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock ↗
It might have a hard time finding a home in the market. 
Via The Motley Fool
News headline image
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug ↗
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative... 
Via Benzinga
News headline image
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
News headline image
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca ↗
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small  
Via Benzinga
News headline image
AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy ↗
AstraZeneca Plc (NASDAQ: AZN) said its PACIFIC 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
Via CannabisNewsWire
Topics Intellectual Property
News headline image
Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip. ↗
Choosing dividend aristocrats to buy becomes easy when you elect to buy the royalty of income-generating stocks. 
Via InvestorPlace
News headline image
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal ↗
Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million... 
Via Talk Markets
News headline image
The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire ↗
These are the next trillion-dollar companies to buy as they represent strong business fundamentals with robust cash flow upside potential. 
Via InvestorPlace
News headline image
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript ↗
AZN earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Auto Trader & AstraZeneca Help FTSE Reverse Early Losses ↗
As the day progressed, the initial downturn was reversed, and the blue-chip index managed to secure gains just shy of 1%. 
Via Talk Markets
News headline image
AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs ↗
The company is licensing a new GLP-1 drug in the hopes of taking on Novo and Lilly. 
Via Investor's Business Daily
News headline image
AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk, Reports Mixed Q3 Earnings ↗
AstraZeneca Plc (NASDAQ: AZN) has reported Q3 FY23 core EPS of $1.73, u 
Via Benzinga
News headline image
Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech ↗
The stock market’s momentum appears to be waning, and futures suggest a mixed opening for Thursday. Earnings reports have generally been positive, with companies like Walt Disney Co. 
Via Benzinga
News headline image
Earnings Review: AstraZeneca Increases Profit Outlook, Reports 17% EPS Growth ↗
AstraZeneca reported an EPS of $1.73 for Q3 2023 and $5.8 for 9M 2023. 
Via Talk Markets
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.